<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000246</url>
  </required_header>
  <id_info>
    <org_study_id>RIFLUVAC</org_study_id>
    <secondary_id>version 2, 21-08-09</secondary_id>
    <nct_id>NCT01000246</nct_id>
  </id_info>
  <brief_title>Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy</brief_title>
  <acronym>RIFLUVAC</acronym>
  <official_title>Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients treated with chemotherapy or immunosuppressives are at higher risk of influenza
      infection and mortality and morbidity are higher compared to healthy adults. Vaccination
      against the influenza virus can prevent these complications. In this study it is investigated
      whether vaccination during chemotherapy is effective in reaching protective serum antibody
      concentrations and the relation between time of vaccination (day 4 +/- 1 day versus day 16
      +/- 1 day of the chemotherapy cycle).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted to answer the question whether vaccination during chemotherapy
      induces an adequate antibody response in oncology patients. Moreover, the effect of the
      timing of the vaccination during a chemotherapy cycle will be evaluated. In the mamma
      carcinoma patients, the effect of early versus late vaccination during a chemotherapy cycle
      will be studied. It was chosen to vaccinate in the early group at day 4 +/- 1 day; the
      immediate influence of the chemotherapy on the vaccination response is expected to have
      passed by then and patients will not already have their nadir. Late vaccination was defined
      as vaccination on day 16 +/- 1 day of the cycle. It is expected that the white blood cell and
      platelet counts by then are normalised.

      In order to define a relatively homogenous patient population with mamma carcinoma, in this
      study patients will be recruited who are treated in the adjuvant setting with FEC-containing
      regimens (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamid 500 mg/m2). The
      results of vaccination in these immunocompromised groups will be compared to the serological
      response to vaccination in persons who receive the influenza vaccination due to heart
      failure. Studies have shown that, although cytotoxic T-cell responses might be diminished,
      the rise in haemagglutinin inhibition titres in patients with heart failure vaccinated
      against influenza can be compared to the response to vaccination in otherwise healthy
      persons. These patients with heart failure will therefore be used as a control group.
      Patients with heart failure who are on treatment with immunosuppressives like prednisolone
      will not be included, because prednisolone diminishes the response to vaccination. The heart
      failure patients will be vaccinated according to the standard influenza vaccination protocol
      in the Netherlands.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate rise in antibody titre</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titres against the influenza virus before and after vaccination</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mamma Carcinoma</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>influenza vaccine day 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>influenza vaccine day 4 of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>influenza vaccine day 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>influenza vaccine day 16 of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza vaccine in patients with heartfailure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza virus vaccine (influvac or vaxigrip)</intervention_name>
    <description>one i.m. dose of 0.5 mL</description>
    <arm_group_label>influenza vaccine day 4</arm_group_label>
    <arm_group_label>influenza vaccine day 16</arm_group_label>
    <arm_group_label>influenza vaccine</arm_group_label>
    <other_name>Influvac, MA number RVG 22289, ATC code J07BB02</other_name>
    <other_name>Vaxigrip, MA number RVG 22306, ATC code J07BB02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mamma carcinoma treated with FEC-containing triweekly chemotherapy at
             moment of vaccination

          -  Patients with heart failure and therefore having an indication for the influenza
             vaccination

          -  Age ≥ 18 years

          -  Signing of informed consent

        Exclusion Criteria:

          -  Fever at time of vaccination defined as a temperature of ≥ 38.5 °C.

          -  Previous/known allergic reaction to any of the components of the vaccines given, for
             example hypersensitivity to egg protein

          -  Thrombocytopenia (defined as &lt; 50 * 109/L ) at moment of vaccination

          -  Treatment with prednisolone on moment of vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Okke de Weerdt, Drs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sint Antonius Hospital Nieuwegein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douwe Biesma, Prof, Dr</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5600 PD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1800 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <state>Noord-Holland</state>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3800 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen</name>
      <address>
        <city>Blaricum</city>
        <state>Utrecht</state>
        <zip>1201 DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>December 17, 2009</last_update_submitted>
  <last_update_submitted_qc>December 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>O. de Weerdt, internist</name_title>
    <organization>Sint Antonius Hospital Nieuwegein</organization>
  </responsible_party>
  <keyword>mammacarcinoma</keyword>
  <keyword>breastcancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>heart failure</keyword>
  <keyword>influenza virus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

